HT
CRSP icon

Headlands Technologies’s CRISPR Therapeutics CRSP Stock Holding History

Headlands Technologies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
24,180
+6,787
+39% +$358K 0.14% 182
2026
Q1 		$827K Buy
+17,393
New +$917K 0.09% 251
2025
Q3 		– Sell
-8,092
Closed -$394K – 752
2025
Q2 		$394K Buy
+8,092
New +$313K 0.05% 357
2024
Q3 		– Sell
-3,440
Closed -$186K – 1248
2024
Q2 		$186K Buy
+3,440
New +$199K 0.02% 495
2023
Q4 		– Sell
-754
Closed -$34.2K – 1000
2023
Q3 		$34.2K Buy
+754
New +$38.9K 0.02% 505

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Headlands Technologies's CRSP Position: Q2 2026 in Review

Headlands Technologies increased its CRISPR Therapeutics (CRSP) stake by 39% in Q2 2026, buying an estimated $358K and bringing the position to 24,180 shares worth $1.32M. The position accounts for 0.14% of the portfolio, ranked #182.

Headlands Technologies first reported a position in CRSP in Q3 2023 and has held it in 5 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Headlands Technologies held 24,180 shares of CRISPR Therapeutics worth $1.32M as of Q2 2026.
  • Headlands Technologies bought 6,787 CRISPR Therapeutics shares in Q2 2026, an estimated $358K.
  • CRISPR Therapeutics made up 0.14% of Headlands Technologies's portfolio in Q2 2026, its #182 holding.
  • Headlands Technologies first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 5 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.